Clinical trials: Moderate to Severe Alzheimer Patients
Healthy Volunteers, Moderate to Severe Alzheimer Patients
A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease
This is a dual-centre, Phase I/IIa study, in healthy subjects and subjects with AD to investigate the safety, tolerability, cognitive, and behavioural effects of RPh201.
- Trial name
- NCT01513967
- Testing
- RPh201, botanical drug product
- Where
- 2 sites in Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Regenera Pharma Ltd
Alzheimer's Disease
Memantine and Changes of Biological Markers and Brain PET Imaging in Alzheimer's Disease
In AD, tau protein is abnormally hyperphosphorylated. Significant changes of hyperphosphorylated tau levels in CSF are found in AD patients.
- Trial name
- NCT00800709
- Testing
- Memantine
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Shanghai Mental Health Center
Alzheimer's Disease
Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease
This is a multi-center, open-label, single-arm, prospective, phase IV trial, evaluating safety and efficacy of donepezil hydrochloride in patients with moderate to severe Alzheimer's disease.
- Trial name
- SAVE (NCT02097056)
- Testing
- Donepezil HCL
- Where
- 13 sites in South Korea
- Volunteers
- 171 people
- Sponsor
- Eisai Korea Inc.
Alzheimer Disease
A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease
No Dimebon clinical data exist yet in patients with disease that has advanced to the moderate-to-severe stage. Therefore, this study evaluates the safety and efficacy of Dimebon in patients with moderate-to-severe AD who are…
- Trial name
- NCT00912288
- Testing
- Dimebon 20 mg po TID
- Where
- 47 sites in United States, Canada and 6 more
- Volunteers
- 86 people
- Sponsor
- Pfizer
Alzheimer Disease
Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease
The goal of this clinical study is to evaluate satisfaction with the use of orodispersible Memantine (OD) versus conventional Memantine tablets (MTb) using the validate SATMED-Q in patients with moderate to severe Alzheimer's…
- Trial name
- NCT07417670
- Testing
- Memantine, Memantine Oral Tablet
- Where
- 4 sites in Mexico
- Volunteers
- 105 people
- Sponsor
- Carnot Laboratories
Alzheimer's Disease
Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease
The primary objective of this study is to examine the efficacy of memantine on cognition and behavioural symptoms in outpatients with moderate to severe dementia of the Alzheimer's type.
- Trial name
- NCT00857649
- Testing
- Memantine
- Where
- 23 sites in Canada
- Volunteers
- 369 people
- Sponsor
- H. Lundbeck A/S
Alzheimer's Disease
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
The primary purpose of this study is to determine whether ELND005 is effective in treating symptoms of agitation and aggression in patients with Alzheimer's disease
- Trial name
- NCT01735630
- Testing
- ELND005
- Where
- 70 sites in United States, Canada and 2 more
- Volunteers
- 350 people
- Sponsor
- OPKO Health, Inc.
Alzheimer's Disease
The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease
Memory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate.
- Trial name
- NCT00090116
- Testing
- Neramexane
- Where
- 34 sites in United States
- Volunteers
- 400 people
- Sponsor
- Forest Laboratories
Moderate to Severe Alzheimer's Disease
GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)
The objective of this study is to evaluate the safety and efficacy of GV1001 administered subcutaneously in patients with moderate to severe Alzheimer's disease (AD).
- Trial name
- NCT05303701
- Testing
- GV1001 1.12mg
- Volunteers
- 750 people
- Sponsor
- Samsung Pharmaceutical Co., Ltd.
Alzheimer Disease (AD)
Study of Neural Stem Cell-Derived Exosomes in Moderate-to-Severe Early-Onset Alzheimer's Disease
This is an open-label, single-center, phase I clinical study in patients with moderate-to-severe early-onset Alzheimer's disease.
- Trial name
- NCT07554872
- Testing
- Neural Stem Cell-Derived Exosomes
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Mental Health Center
Dementia of the Alzheimer's Type
A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease
The objective of this study is to evaluate the safety, tolerability, and efficacy of memantine compared to placebo in outpatients diagnosed with moderate-to-severe dementia of the Alzheimer's type on a concurrent…
- Trial name
- NCT00322153
- Testing
- memantine ER
- Where
- 83 sites in United States, Argentina and 2 more
- Volunteers
- 677 people
- Sponsor
- Forest Laboratories
Mild, Moderate, or Severe Alzheimer's Disease
A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients
An open-label, exploratory, phase II, proof-of concept, clinical study to assess the safety and tolerability of EI-1071 and the effects of EI-1071 on neuroinflammation in patients with mild, moderate, or severe Alzheimer's disease
- Trial name
- NCT06745583
- Testing
- EI-1071 tablet, oral
- Where
- 2 sites in Taiwan
- Volunteers
- 7 people
- Sponsor
- Elixiron Immunotherapeutics Inc.
Alzheimer's Disease
Memantine and Antipsychotics Use
To investigate the potential to reduce concomitant antipsychotic medication use in subjects with moderate dementia of Alzheimer's type, treated with memantine.
- Trial name
- MemAP (NCT00649220)
- Testing
- Memantine
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Merz Pharmaceuticals GmbH
Alzheimer Disease, Lewy Body Dementia (LBD)
Deep Cervical Lymphaticovenous Anastomosis Surgery for Moderate-to-Advanced Dementia Patients
This clinical trial aims to evaluate the clinical efficacy and safety of Deep Cervical Lymphaticovenous Anastomosis (DLVA) in patients aged 50-80 with moderate to severe neurodegenerative dementia.
- Conditions
- Alzheimer Disease, Lewy Body Dementia (LBD), Frontotemporal Dementia (FTD), Dementia
- Trial name
- NCT06978946
- Testing
- Deep Cervical Lymphaticovenous Anastomosis(DLVA)
- Where
- China
- Volunteers
- 85 people
- Sponsor
- RenJi Hospital
Alzheimer's Disease
Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease
The primary objective of the study was to examine the safety and tolerability of memantine in outpatients with moderate to severe Alzheimer's Disease.
- Trial name
- NCT00857233
- Testing
- Memantine
- Where
- 33 sites in Canada
- Volunteers
- 297 people
- Sponsor
- H. Lundbeck A/S
Alzheimer's Disease
Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease
The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with moderate to severe Alzheimer's disease.
- Trial name
- NCT00478205
- Testing
- Aricept (donepezil SR 23 mg), Aricept (donepezil IR 10 mg)
- Where
- United States
- Volunteers
- 1,467 people
- Sponsor
- Eisai Inc.
Alzheimer's Disease
An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease
About 65% of patients with severe Alzheimer's Disease (AD) will have symptoms of agitation. There are drawbacks associated with the currently available therapeutic interventions for agitation associated with Alzheimer's Disease.
- Trial name
- NCT00097916
- Testing
- memantine HCl
- Where
- 9 sites in United States
- Volunteers
- 34 people
- Sponsor
- Forest Laboratories
Alzheimer's Disease
A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to compare the effectiveness and safety of 2 years of treatment with galantamine as compared with placebo of patients who have mild to moderately severe Alzheimer's disease (AD).
- Trial name
- NCT00679627
- Testing
- Galantamine
- Where
- 95 sites in Czechia, Estonia and 10 more
- Volunteers
- 2,051 people
- Sponsor
- Janssen Research & Development, LLC
Alzheimer's Disease, Dementia
Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease
This study will evaluate the pharmacological efficacy on language capability and compliance with combination of new Ebixa oral pump and donepezil compared to donepezil only in patients with probable Alzheimer's disease.
- Trial name
- ROMEO-AD (NCT01849042)
- Testing
- Ebixa, donepezil
- Where
- South Korea
- Volunteers
- 188 people
- Sponsor
- Konkuk University Medical Center
Alzheimer's Disease, Dementia
Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients
The primary aim is to determine whether Divalproex ER or one of the atypical antipsychotics is more effective improving dementia related behavioral symptoms in patients with dementia, and evaluate the impact of such improvements…
- Conditions
- Alzheimer's Disease, Dementia, Behavioral Symptoms
- Trial name
- NCT00375557
- Testing
- Divalproex ER, Quetiapine
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Cincinnati